NNC0519-0130
Phase 2Small molecule
Novo NordiskNNC0519-0130 is one of 80 small molecule programs targeting Overweight. It is currently in Phase 2.
3
Indications
11
Total Trials
3
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
169 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Uloric
TakedaPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Sovaldi
GileadPreclinical
NNC0519-0130
Novo NordiskPhase 2
Activase
RochePreclinical
Flomax
SanofiPreclinical
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Viagra
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes2 trials
Overweight2 trials
Body Weight2 trials
Menopause1 trial
3 more indications
Function1 trial
Diabetes Mellitus, Type 21 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NNC0519-0130. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company